No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 712 | 736 | 769 | 796 | 851 | 786 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 18 | 33 | -41 | 24 | 16 | -108 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Guerbet SA is dedicated to the development and commercialization of a broad spectrum of contrast media, advanced delivery systems, medical devices, and related solutions for diagnostic imaging. Their extensive product lineup features iodinated contrast agents such as Optiray and Xenetix, both non-ionic monomeric; Telebrix Gastro, a meglumine ioxitalamate solution; and Conray, an iothalamate meglumine injection. They also offer Micropaque/Microtrast, an integrated diagnostic imaging solution. For MRI applications, the company provides gadoteric acid-based contrast agents like Dotarem (gadoterate meglumine) and Artirem. Complementing these are essential delivery systems and consumables, including prefilled syringes, injectors, and accessories designed for use in MRI, CT, and Cath Lab settings. Guerbet also delivers innovative digital health solutions such as Contrast&Care for injection management, Dose&Care for X-ray dose management, and icobrain, a cloud-based AI platform that quantifies disease-specific brain structures from MR and CT scans for acute and chronic neurological conditions. Additionally, they offer OptiProtect services. In the realm of interventional radiology, the company provides products like Lipiodol (ethyl esters of iodinated fatty acids of poppyseed oil), Vectorio (a mixing and injection system for conventional trans-arterial chemoembolization), Patent Blue V (a blue dye), Axessio (a peripheral micro guidewire), and microcatheters such as SeQure and DraKon. Furthermore, their offerings include Hydra Vision, a digital imaging system tailored for urological, gastroenterological, and gynecological treatment, planning, and diagnostic procedures, alongside various urology accessories and consumables. Established in 1926, Guerbet's headquarters are situated in Villepinte, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Guerbet SA is dedicated to the development and commercialization of a broad spectrum of contrast media, advanced delivery systems, medical devices, and related solutions for diagnostic imaging. Their extensive product lineup features iodinated contrast agents such as Optiray and Xenetix, both non-ionic monomeric; Telebrix Gastro, a meglumine ioxitalamate solution; and Conray, an iothalamate meglumine injection. They also offer Micropaque/Microtrast, an integrated diagnostic imaging solution. For MRI applications, the company provides gadoteric acid-based contrast agents like Dotarem (gadoterate meglumine) and Artirem. Complementing these are essential delivery systems and consumables, including prefilled syringes, injectors, and accessories designed for use in MRI, CT, and Cath Lab settings. Guerbet also delivers innovative digital health solutions such as Contrast&Care for injection management, Dose&Care for X-ray dose management, and icobrain, a cloud-based AI platform that quantifies disease-specific brain structures from MR and CT scans for acute and chronic neurological conditions. Additionally, they offer OptiProtect services. In the realm of interventional radiology, the company provides products like Lipiodol (ethyl esters of iodinated fatty acids of poppyseed oil), Vectorio (a mixing and injection system for conventional trans-arterial chemoembolization), Patent Blue V (a blue dye), Axessio (a peripheral micro guidewire), and microcatheters such as SeQure and DraKon. Furthermore, their offerings include Hydra Vision, a digital imaging system tailored for urological, gastroenterological, and gynecological treatment, planning, and diagnostic procedures, alongside various urology accessories and consumables. Established in 1926, Guerbet's headquarters are situated in Villepinte, France.